United StatesBreaking News

T. Rowe Price Group (NASDAQ:TROW) reported month-end assets under management (AUM) of $1.89 trillion as of May 31, 2026.

Dan Ives of Wedbush Securities talks about the upcoming SpaceX IPO and how it could impact tech stocks. He speaks on "Bloomberg Surveillance."

Henry McVey, balance sheet CIO and head of global asset and macro allocation at KKR, discusses his expectations for the upcoming Federal Reserve decision and offers insight into the firm's midyear outlook.

ParaZero Technologies (NASDAQ:PRZO) announced that it has secured two purchase orders in Israel for its DefendAir Net Pod system, marking a significant step in integrating its autonomous Counter-UAS technology into advanced defense platforms.

Paramount Skydance's (NASDAQ:PSKY) proposed $110 billion acquisition of Warner Bros. Discovery (NASDAQ:WBD) has come under formal scrutiny from the European Union over its financial backing from Middle Eastern sovereign wealth funds, according to a European Commission filing.

Figure Technology Solutions (NASDAQ:FIGR) announced a definitive agreement to acquire Kiavi, an AI-powered lending platform tailored for residential real estate investors, in a transaction valued at $717 million.

Scinai Immunotherapeutics (NASDAQ:SCNI) reported a net profit for the first quarter of fiscal year 2026, driven primarily by a substantial, non-cash accounting gain linked to its recent acquisition of Recipharm Israel.

Cullinan Therapeutics (NASDAQ:CGEM) reported encouraging initial clinical data and outlined expanded development pathways for its portfolio of dual-targeting T-cell engagers, marking an expansion for the oncology-focused biotech into the autoimmune space.

Taiwan Semiconductor Manufacturing Co. reported monthly sales rose 30%, reflecting continued strength in global demand spurred by a rush to build AI infrastructure. Neil Campling reports on Bloomberg Television.

Artelo Biosciences (NASDAQ:ARTL) announced encouraging human metabolite identification and profiling data for its lead drug candidate, ART26.12, as the biotechnology company aims to de-risk the development of its novel non-opioid pain therapy.

Organon (NYSE:OGN) announced that the US Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for Tofidence, expanding the therapeutic indications of the drug within the competitive US biosimilars market.

President Donald Trump posted a warning on social media Wednesday that Iran has taken too long to come to terms and will "pay the price." Tyler Kendall reports on Bloomberg Television.